Payment overview · 2025
General Payments
$684.36
38 reported records · 17 companies
Healthcare provider profile · identity verified
Ellis Frazier, MD
Allopathic & Osteopathic Physicians|Family Medicine · PIKETON, OH · NPI 1245228196
Verified facts
What the public records show
CMS Open Payments records show Ellis Frazier, MD received $684.36 in general payments during 2025 across 38 reported records.
ABBVIE INC. accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Descovy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $148.97 | 21.8% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $64.43 | 9.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.76 | 7.4% | 3 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $50.71 | 7.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.18 | 6.2% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $41.04 | 6.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $36.55 | 5.3% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $35.31 | 5.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.98 | 4.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.85 | 4.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.50 | 4.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.16 | 4.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.27 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.58 | 2.9% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $17.98 | 2.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.75 | 2.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $16.34 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $639.36 | 37 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.12 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $59.93 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.28 | 5 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $50.71 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $43.79 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $41.04 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $36.55 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.98 | 4 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $27.57 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.50 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.16 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
96 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
77 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 562 | 75 |
| Omeprazole | Omeprazole | 554 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 443 | 55 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 416 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 391 | 82 |
| Oxycodone Hcl | Oxycodone Hcl | 367 | 42 |
| Alprazolam | Alprazolam | 363 | 40 |
| Lisinopril | Lisinopril | 345 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 340 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 295 | 37 |
| Losartan Potassium | Losartan Potassium | 256 | 56 |
| Clonazepam | Clonazepam | 251 | 31 |
| Metformin Hcl | Metformin Hcl | 235 | 46 |
| Furosemide | Furosemide | 230 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 208 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 35 |
| Potassium Chloride | Potassium Chloride | 186 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 180 | 36 |
| Sertraline Hcl | Sertraline Hcl | 180 | 22 |
| Lorazepam | Lorazepam | 169 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 165 | 23 |
| Ibuprofen | Ibuprofen | 162 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 28 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 147 | 13 |
| Tramadol Hcl | Tramadol Hcl | 144 | 24 |
| Trazodone Hcl | Trazodone Hcl | 144 | 22 |
| Diazepam | Diazepam | 143 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 28 |
| Warfarin Sodium | Warfarin Sodium | 137 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 25 |
| Prednisone | Prednisone | 130 | 43 |
| Indapamide | Indapamide | 128 | 14 |
| Carvedilol | Carvedilol | 123 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 28 |
| Eliquis | Apixaban | 118 | 19 |
| Spironolactone | Spironolactone | 116 | 26 |
| Nystatin | Nystatin | 113 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 107 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 104 | 19 |
| Montelukast Sodium | Montelukast Sodium | 103 | 16 |
| Ozempic | Semaglutide | 99 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 97 | 13 |
| Mounjaro | Tirzepatide | 96 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 20 |
| Glimepiride | Glimepiride | 90 | 15 |
| Ezetimibe | Ezetimibe | 82 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 81 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 12 |
| Trulicity | Dulaglutide | 77 | 11 |
| Famotidine | Famotidine | 76 | 14 |
| Allopurinol | Allopurinol | 75 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 11 |
| Xarelto | Rivaroxaban | 74 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 73 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 71 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | suppressed |
| Meloxicam | Meloxicam | 67 | 13 |
| Fluconazole | Fluconazole | 66 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 63 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 14 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 62 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 11 |
| Jardiance | Empagliflozin | 60 | suppressed |
| Bupropion Xl | Bupropion Hcl | 59 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | 13 |
| Topiramate | Topiramate | 58 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | suppressed |
| Ketoconazole | Ketoconazole | 56 | suppressed |
| Pregabalin | Pregabalin | 56 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 55 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 54 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 53 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 53 | suppressed |
| Celecoxib | Celecoxib | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | suppressed |
| Mupirocin | Mupirocin | 48 | 24 |
| Risperidone | Risperidone | 48 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 12 |
| Azithromycin | Azithromycin | 45 | 30 |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Tradjenta | Linagliptin | 45 | suppressed |
| Levetiracetam | Levetiracetam | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Simvastatin | Simvastatin | 44 | 11 |
| Temazepam | Temazepam | 44 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 43 | 42 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 11 |
| Torsemide | Torsemide | 41 | suppressed |
| Cefdinir | Cefdinir | 40 | 30 |
| Juluca | Dolutegravir/Rilpivirine | 40 | suppressed |
| Mirtazapine | Mirtazapine | 40 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 12 |
| Ranolazine Er | Ranolazine | 39 | suppressed |
| Calcitriol | Calcitriol | 38 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 13 |
| Atenolol | Atenolol | 36 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 36 | suppressed |
| Roflumilast | Roflumilast | 35 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Acyclovir | Acyclovir | 32 | suppressed |
| Cephalexin | Cephalexin | 32 | 20 |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 32 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 31 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 31 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 18 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 12 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Testosterone | Testosterone | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 14 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 24 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 24 | 21 |
| Rybelsus | Semaglutide | 24 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 23 | suppressed |
| Tivicay | Dolutegravir Sodium | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Delstrigo | Doravirine/Lamivu/Tenofov Diso | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Nyamyc | Nystatin | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 17 | suppressed |
| Dulera | Mometasone/Formoterol | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Enbrel Sureclick | Etanercept | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Np Thyroid | Thyroid,pork | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Tegretol | Carbamazepine | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $684.36 · 38 records | ABBVIE INC. | AIRSUPRA, APRETUDE, AUSTEDO XR, BREZTRI, Cologuard Collection Kit, FANAPT, INGREZZA, INSPIRE, Kerendia, MAVYRET, MOUNJARO, Natroba, QULIPTA, REXULTI, Spinosad, TRULANCE, UBRELVY, UZEDY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error